Trimethobenzamide

Revision as of 09:10, 1 May 2023 by Zbuchwald (talk | contribs) (Created page with "==Administration== *Type: Antiemetic *Dosage Forms: 200mg, 300mg *Routes of Administration: IM, PO *Common Trade Names: Tigan ==Adult Dosing== *Nausea/Vomiting: 200mg IM q8h prn, 300mg PO q8h prn **Can be used as an antiemetic in patients with a prolonged QTc ==Pediatric Dosing== *Expert recommendations for nausea and vomiting management do not suggest trimethobenzamide as a therapeutic option; use has been replaced by newer agents with an improved safety profile ==Sp...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Antiemetic
  • Dosage Forms: 200mg, 300mg
  • Routes of Administration: IM, PO
  • Common Trade Names: Tigan

Adult Dosing

  • Nausea/Vomiting: 200mg IM q8h prn, 300mg PO q8h prn
    • Can be used as an antiemetic in patients with a prolonged QTc

Pediatric Dosing

  • Expert recommendations for nausea and vomiting management do not suggest trimethobenzamide as a therapeutic option; use has been replaced by newer agents with an improved safety profile

Special Populations

Pregnancy Rating

Lactation risk

Renal Dosing

  • Adult:
  • Pediatric:

Hepatic Dosing

  • Adult:
  • Pediatric:

Contraindications

  • Allergy to class/drug
  • Hypersensitivity to trimethobenzamide or any component of the formulation
  • Use in pediatric patients (injection only)

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 7 to 9 hours
  • Metabolism: Via oxidation, forms metabolite trimethobenzamide N-oxide
  • Excretion: Urine (30% to 50%, as unchanged drug)

Mechanism of Action

  • Acts centrally to inhibit the medullary chemoreceptor trigger zone by blocking emetic impulses to the vomiting center

Comments

No known QTc prolonging effects, consider as an alternative in patients where

See Also

References

Retrieved from "https://www.wikem.org/w/index.php?title=Trimethobenzamide&oldid=370036"